Clinical safety of oral sildenafil citrate (VIAGRA®) in the treatment of erectile dysfunction

International Journal of Impotence Research

Volumn 10, Issue 2, 1998, Pages 69-74

  Morales, A ^a,e   Gingell, C ^b   Collins, M ^c   Wicker, P A ^d   Osterloh, I H ^c  

^a QUEEN S UNIVERSITY   (Canada)

^b SOUTHMEAD HOSPITAL   (United Kingdom)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^e KINGSTON GENERAL HOSPITAL   (Canada)

Author keywords

Erectile dysfunction; Phosphodiesterase type 5 inhibitor; Safety; Sildenafil

Indexed keywords

SILDENAFIL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; HEADACHE; HOT FLUSH; HUMAN; IMPOTENCE; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; NOSE CONGESTION; ORAL DRUG ADMINISTRATION; PENIS ERECTION; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; URINARY TRACT INFECTION; VERTIGO; VISUAL DISORDER;

EID: 0031861609     PISSN: 09559930     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ijir.3900354     Document Type: Article

References (11)

1. Boolell M, Gepi-Attee S, Gingell JC, Allen MJ. Sildenafil, a novel effective oral therapy for male erectile dysfunction. Br J Urol 1996; 78: 257-261.
2. Ballard SA et al. Sildenafil, an inhibitor of phosphodiesterase type 5, enhances nitric oxide mediated relaxation of human corpus cavernosum. Int J Impot Res 1996; 8: 103. Abstract.
3. Rajfer J et al. Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med 1992; 326: 90-94.
4. Burnett AL. Nitric oxide in the penis: physiology and pathology. J Urol 1997; 157: 320-324.
5. Wagner G, Saenz de Tejada I. Update on male erectile dysfunction. BMJ 1998; 316: 678-682.
6. Andersson K-E, Wagner G. Physiology of penile erection. Physiol Rev 1995; 75: 191-236.
7. Boolell M et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erection dysfunction. Int J Impot Res 1996; 8: 47-52.
8. Goldstein I et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998. In press.
9. Das S, Kumar KN. Nitric oxide: its identity and role in blood pressure control. Life Sci 1995; 57: 1547-1556.
10. Vallance P. Control of the human cardiovascular system by nitric oxide. J Hum Hypertens 1996; 10: 377-381.
11. Virag R at al. Sildenafil (VIAGRA™), a new oral treatment for erectile dysfunction (ED): an 8 week double-blind, placebo-controlled parallel group study. Int J Impot Res 1996; 8: 116. Abstract.